Nathalie Moll

Nathalie Moll

Nathalie Moll is Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Imagining a future where rare diseases patients have a better chance at a healthy life Partner Content
21 Feb
Imagining a future where rare diseases patients have a better chance at a healthy life
Past legislation has inspired impressive medicines development in Europe and we must continue to drive progress to deliver new, life-changing therapies
Innovation is delivering therapies for people with rare diseases – but R&D needs support Partner Content
22 Feb
Innovation is delivering therapies for people with rare diseases – but R&D needs support
Investment in R&D in Europe is vital if we are to tackle unmet medical needs, says Nathalie Moll
Rare Diseases: EU Orphan Regulation, backing innovation to address unmet needs Partner Content
23 Feb
Rare Diseases: EU Orphan Regulation, backing innovation to address unmet needs
Our capacity to keep on developing new treatments for people living with rare disease depends on Europe’s research ecosystem
Rare Diseases: Why medical innovation needs to be one step ahead Partner Content
24 Feb
Rare Diseases: Why medical innovation needs to be one step ahead
Accelerating innovation key to ensuring that no one is left behind in fight against rare diseases, says Nathalie Moll EFPIA Director General.
Health after COVID-19: spend more but spend smarter Partner Content
13 Oct
Health after COVID-19: spend more but spend smarter
As we enter the final stretch of 2020, we face a huge dilemma for public health and public finances: how do we manage the massive impact of COVID-19 and the increasing burden of chronic diseases without bankrupting public finances?
EU Pharmaceutical Strategy could be a lost opportunity if action is not taken now Partner Content
02 Jul
EU Pharmaceutical Strategy could be a lost opportunity if action is not taken now
In its current form, the pharma strategy roadmap lacks the necessary drivers of innovation to put Europe back at the forefront of medical discovery, writes Nathalie Moll
A new EU industrial strategy would drive health and growth Partner Content
05 Nov
A new EU industrial strategy would drive health and growth
Europe must play to its strengths and pharma is an area of strategic economic and social value where the EU is a global player, writes EFPIA's Nathalie Moll.
Innovation and R&D are the keys to a healthier future Partner Content
07 Apr
Innovation and R&D are the keys to a healthier future
Innovation and R&D are the keys to a healthier future, explains Nathalie Moll.
EU Comitology reform threatens innovation in a post-truth world Partner Content
15 Mar
EU Comitology reform threatens innovation in a post-truth world
As the world looks to Europe to lead on evidence-based decision-making, we must not let politics trump science, warns Nathalie Moll.
PM+: GMO authorisation needs legal certainty Partner Content
26 Oct
PM+: GMO authorisation needs legal certainty
Ahead of the European Parliament’s vote on the use of GMOs, Nathalie Moll calls for a shift to a more coherent and science-based approach to EU policymaking.